To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced, unfavorable Hodgkin's lymphoma (HL). Patients and Methods: One hundred sixty-three patients achieving complete remission (CR) or partial remission (PR) with four initial courses of doxorubicin, bleomycin, vinblastine, and dacarbazine, or other doxorubicin-containing regimens, were randomly assigned to receive HDT plus ASCT (83 patients) versus four courses of conventional chemotherapy (80 patients). Unfavorable HL was defined as the presence of at least two of the following poor prognostic factors: high lactate dehydrogenase level, large mediastinal mass (greater then at least 33%. of the thoracic diameter), more than one extranodal site, low hematocrit level, and inguinal involvement. Results. At the end of the treatment program, 92% of patients in arm A and 89% in arm 8 achieved a CR (P = .6). After a median follow-up of 48 months, the 5-year failure-free survival rates were 75% (95% confidence interval [CI], 65 to 85) in arm A and 82% (95% CI, 73 to 90) in arm B (P = .4). The 5-year overall survival rates were 89% (95% CI, 90 to 96) in arm A and 88%. (95% CI, 79 to 96) in arm B (P = .99). The 5-year relapse-free survival rates were 88% in arm A (95% CI, 80 to 96) and 94% in arm 6 (95% CI, 88 to 100), and the difference was not significant (P = .3). Conclusion: Patients with advanced unfavorable HL achieving CR or PR after four courses of doxorubicin-containing regimens have a favorable outcome with conventional chemotherapy. No benefit from an early intensification with HDT and ASCT was shown.

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy / Federico, Massimo; Bellei, Monica; Brice, P; Brugiatelli, M; Nagler, A; Gisselbrecht, C; Moretti, L; Colombat, P; Luminari, Stefano; Fabbiano, F; Di Renzo, N; Goldstone, A; Carella, Am. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 21:(2003), pp. 2320-2325. [10.1200/JCO.2003.11.103]

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy

FEDERICO, Massimo;BELLEI, Monica;LUMINARI, Stefano;
2003

Abstract

To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced, unfavorable Hodgkin's lymphoma (HL). Patients and Methods: One hundred sixty-three patients achieving complete remission (CR) or partial remission (PR) with four initial courses of doxorubicin, bleomycin, vinblastine, and dacarbazine, or other doxorubicin-containing regimens, were randomly assigned to receive HDT plus ASCT (83 patients) versus four courses of conventional chemotherapy (80 patients). Unfavorable HL was defined as the presence of at least two of the following poor prognostic factors: high lactate dehydrogenase level, large mediastinal mass (greater then at least 33%. of the thoracic diameter), more than one extranodal site, low hematocrit level, and inguinal involvement. Results. At the end of the treatment program, 92% of patients in arm A and 89% in arm 8 achieved a CR (P = .6). After a median follow-up of 48 months, the 5-year failure-free survival rates were 75% (95% confidence interval [CI], 65 to 85) in arm A and 82% (95% CI, 73 to 90) in arm B (P = .4). The 5-year overall survival rates were 89% (95% CI, 90 to 96) in arm A and 88%. (95% CI, 79 to 96) in arm B (P = .99). The 5-year relapse-free survival rates were 88% in arm A (95% CI, 80 to 96) and 94% in arm 6 (95% CI, 88 to 100), and the difference was not significant (P = .3). Conclusion: Patients with advanced unfavorable HL achieving CR or PR after four courses of doxorubicin-containing regimens have a favorable outcome with conventional chemotherapy. No benefit from an early intensification with HDT and ASCT was shown.
2003
21
2320
2325
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy / Federico, Massimo; Bellei, Monica; Brice, P; Brugiatelli, M; Nagler, A; Gisselbrecht, C; Moretti, L; Colombat, P; Luminari, Stefano; Fabbiano, F; Di Renzo, N; Goldstone, A; Carella, Am. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 21:(2003), pp. 2320-2325. [10.1200/JCO.2003.11.103]
Federico, Massimo; Bellei, Monica; Brice, P; Brugiatelli, M; Nagler, A; Gisselbrecht, C; Moretti, L; Colombat, P; Luminari, Stefano; Fabbiano, F; Di Renzo, N; Goldstone, A; Carella, Am
File in questo prodotto:
File Dimensione Formato  
JCO-2003-Federico-2320-5.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 194.64 kB
Formato Adobe PDF
194.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/5165
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 114
  • ???jsp.display-item.citation.isi??? 85
social impact